Opko Health Inc (NASDAQ:OPK) — Market Cap & Net Worth
Market Cap & Net Worth: Opko Health Inc (OPK)
Opko Health Inc (NASDAQ:OPK) has a market capitalization of $1.16 Billion ($1.16 Billion) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8268 globally and #2427 in its home market, demonstrating a -3.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Opko Health Inc's stock price $1.56 by its total outstanding shares 746328225 (746.33 Million). Also see how large is Opko Health Inc's balance sheet for a full breakdown of the balance sheet.
Opko Health Inc Market Cap History: 2015 to 2026
Opko Health Inc's market capitalization history from 2015 to 2026. Data shows change from $7.50 Billion to $1.16 Billion (-15.77% CAGR). Also see Opko Health Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Opko Health Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.10% | #23 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.04% | #243 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.00% | #903 of 3165 |
Weight: Opko Health Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Opko Health Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Opko Health Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Opko Health Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.55x
Opko Health Inc's market cap is 1.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.94 Billion | $1.22 Billion | -$48.36 Million | 5.68x | N/A |
| 2017 | $3.66 Billion | $966.01 Million | -$305.25 Million | 3.79x | N/A |
| 2018 | $2.25 Billion | $990.30 Million | -$153.04 Million | 2.27x | N/A |
| 2019 | $1.10 Billion | $901.93 Million | -$314.93 Million | 1.22x | N/A |
| 2020 | $2.95 Billion | $1.44 Billion | $30.59 Million | 2.05x | 96.38x |
| 2021 | $3.59 Billion | $1.77 Billion | -$30.14 Million | 2.02x | N/A |
| 2022 | $932.91 Million | $1.00 Billion | -$328.40 Million | 0.93x | N/A |
| 2023 | $1.13 Billion | $863.50 Million | -$188.86 Million | 1.31x | N/A |
| 2024 | $1.10 Billion | $713.14 Million | -$53.22 Million | 1.54x | N/A |
| 2025 | $940.37 Million | $606.88 Million | -$225.68 Million | 1.55x | N/A |
Competitor Companies of OPK by Market Capitalization
Companies near Opko Health Inc in the global market cap rankings as of September 15, 2026. Review Opko Health Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Opko Health Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #167 globally with a market cap of $143.57 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #473 globally with a market cap of $57.49 Billion USD ( CN¥392.91 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #578 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $613.62 |
| #167 | Danaher Corporation | NYSE:DHR | $143.57 Billion | $203.25 |
| #473 | WuXi AppTec Co Ltd | SHG:603259 | $57.49 Billion | CN¥158.86 |
| #578 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $341.79 |
Opko Health Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Opko Health Inc's market cap moved from $7.50 Billion to $ 1.16 Billion, with a yearly change of -15.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.16 Billion | +23.81% |
| 2025 | $940.37 Million | -14.29% |
| 2024 | $1.10 Billion | -2.65% |
| 2023 | $1.13 Billion | +20.80% |
| 2022 | $932.91 Million | -74.01% |
| 2021 | $3.59 Billion | +21.77% |
| 2020 | $2.95 Billion | +168.71% |
| 2019 | $1.10 Billion | -51.16% |
| 2018 | $2.25 Billion | -38.57% |
| 2017 | $3.66 Billion | -47.31% |
| 2016 | $6.94 Billion | -7.46% |
| 2015 | $7.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Opko Health Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.16 Billion USD |
| MoneyControl | $1.16 Billion USD |
| MarketWatch | $1.16 Billion USD |
| marketcap.company | $1.16 Billion USD |
| Reuters | $1.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Opko Health Inc
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigen… Read more